• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

极向量法评估肠易激综合征治疗效果:对100mg匹维溴铵加300mg西甲硅油口服,每日两次的分析

Polar vectors as a method for evaluating the effectiveness of irritable bowel syndrome treatments: an analysis with pinaverium bromide 100mg plus simethicone 300mg po bid.

作者信息

López-Alvarenga J C, Sobrino-Cossío S, Remes-Troche J M, Chiu-Ugalde J, Vargas-Romero J A, Schmulson M

机构信息

Research Office, Hospital General de México O.D., Mexico City, Mexico.

出版信息

Rev Gastroenterol Mex. 2013 Jan-Mar;78(1):21-7. doi: 10.1016/j.rgmx.2012.10.003. Epub 2013 Feb 1.

DOI:10.1016/j.rgmx.2012.10.003
PMID:23375823
Abstract

BACKGROUND

Irritable Bowel Syndrome (IBS) is a disorder characterized by abdominal pain or discomfort associated with changes in bowel habit. Currently there are no objective outcome measures for evaluating the effectiveness of treatments for this disorder.

AIMS

To determine the usefulness of a method of analysis that employs polar vectors to evaluate the effectiveness of IBS treatments.

METHODS

Data from a Phase IV clinical study with 1677 active IBS-Rome III patients who received 100mg of pinaverium bromide+300mg of simethicone (PB+S) po bid for a period of four weeks were used for the analysis. Using the Bristol Stool Scale as a reference, the consistency and frequency of each type of bowel movement were recorded weekly in a Bristol Matrix (BM) and the data were expressed as polar vectors.

RESULTS

The analysis showed a differential response to the PB+S treatment among the IBS subtypes: in reference to the IBS with constipation subtype, the magnitude of the vector increased from 10.2 to 12.5, reaching maximum improvement at two weeks of treatment (p<0.05, Scheffé). In the IBS with diarrhea and mixed IBS subtypes, the magnitude of the vector decreased from 19 to 14 (p<0.05) and from 16.5 to 13 (p<0.05), respectively, with continuous improvement for a period of four weeks. There was no definable vectorial pattern in the unsubtyped IBS group.

CONCLUSIONS

Analysis with polar vectors enables treatment response to be measured in different IBS subtypes. All the groups showed improvement with PB+S, but each one had its own characteristic response in relation to vector magnitude and direction. The proposed method can be implemented in clinical studies to evaluate the efficacy of IBS treatments.

摘要

背景

肠易激综合征(IBS)是一种以腹痛或不适并伴有排便习惯改变为特征的疾病。目前尚无用于评估该疾病治疗效果的客观结局指标。

目的

确定一种采用极坐标向量来评估IBS治疗效果的分析方法的实用性。

方法

来自一项IV期临床研究的数据被用于分析,该研究中有1677例活动性IBS-Rome III患者,他们口服100mg匹维溴铵+300mg西甲硅油(PB+S),每日两次,为期四周。以布里斯托大便分类法为参考,每周在布里斯托矩阵(BM)中记录每种排便类型的稠度和频率,数据以极坐标向量表示。

结果

分析显示IBS各亚型对PB+S治疗有不同反应:相对于便秘型IBS亚型,向量大小从10.2增加到12.5,在治疗两周时达到最大改善(p<0.05,谢费检验)。在腹泻型IBS和混合型IBS亚型中,向量大小分别从19降至14(p<0.05)和从16.5降至13(p<0.05),并在四周内持续改善。未分型IBS组中没有可明确的向量模式。

结论

用极坐标向量进行分析能够测量不同IBS亚型的治疗反应。所有组使用PB+S后均有改善,但每组在向量大小和方向方面都有其自身的特征性反应。所提出的方法可应用于临床研究以评估IBS治疗的疗效。

相似文献

1
Polar vectors as a method for evaluating the effectiveness of irritable bowel syndrome treatments: an analysis with pinaverium bromide 100mg plus simethicone 300mg po bid.极向量法评估肠易激综合征治疗效果:对100mg匹维溴铵加300mg西甲硅油口服,每日两次的分析
Rev Gastroenterol Mex. 2013 Jan-Mar;78(1):21-7. doi: 10.1016/j.rgmx.2012.10.003. Epub 2013 Feb 1.
2
A randomized double-blind placebo-controlled clinical trial on efficacy and safety of association of simethicone and Bacillus coagulans (Colinox®) in patients with irritable bowel syndrome.西甲硅油与凝结芽孢杆菌(Colinox®)联合应用于肠易激综合征患者疗效和安全性的随机双盲安慰剂对照临床试验
Eur Rev Med Pharmacol Sci. 2014;18(9):1344-53.
3
Importance of diarrhea in evaluating constipation in irritable bowel syndrome clinical studies.腹泻在评估肠易激综合征临床研究中便秘的重要性。
J Clin Gastroenterol. 2011 Oct;45(9):790-3. doi: 10.1097/MCG.0b013e3182053cea.
4
Efficacy of the Combination of Pinaverium Bromide 100 mg Plus Simethicone 300 mg in Abdominal Pain and Bloating in Irritable Bowel Syndrome: A Randomized, Placebo-controlled Trial.匹维溴铵 100mg 联合西甲硅油 300mg 治疗肠易激综合征腹痛腹胀的疗效:一项随机、安慰剂对照试验。
J Clin Gastroenterol. 2020 Apr;54(4):e30-e39. doi: 10.1097/MCG.0000000000001242.
5
Pinaverium Reduces Symptoms of Irritable Bowel Syndrome in a Multicenter, Randomized, Controlled Trial.在一项多中心、随机、对照试验中,匹维溴铵可减轻肠易激综合征的症状。
Clin Gastroenterol Hepatol. 2015 Jul;13(7):1285-1292.e1. doi: 10.1016/j.cgh.2015.01.015. Epub 2015 Jan 26.
6
Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.在一项 2 期研究中,Eluxadoline 使腹泻型肠易激综合征患者受益。
Gastroenterology. 2013 Aug;145(2):329-38.e1. doi: 10.1053/j.gastro.2013.04.006. Epub 2013 Apr 9.
7
A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.一项关于利那洛肽治疗便秘型肠易激综合征的临床疗效的综述。
Curr Med Res Opin. 2013 Feb;29(2):149-60. doi: 10.1185/03007995.2012.754743. Epub 2012 Dec 20.
8
Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.贝得石蒙脱石对肠易激综合征的症状疗效:一项随机对照试验
Aliment Pharmacol Ther. 2005 Feb 15;21(4):435-44. doi: 10.1111/j.1365-2036.2005.02330.x.
9
Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification.肠易激综合征亚型的短期稳定性:采用 Rome III 分类的前瞻性评估。
Aliment Pharmacol Ther. 2012 Feb;35(3):350-9. doi: 10.1111/j.1365-2036.2011.04948.x. Epub 2011 Dec 18.
10
Subtyping the irritable bowel syndrome by predominant bowel habit: Rome II versus Rome III.根据主要排便习惯对肠易激综合征进行亚型分类:罗马II标准与罗马III标准对比
Aliment Pharmacol Ther. 2007 Sep 15;26(6):953-61. doi: 10.1111/j.1365-2036.2007.03422.x.

引用本文的文献

1
Efficacy of the Combination of Pinaverium Bromide 100 mg Plus Simethicone 300 mg in Abdominal Pain and Bloating in Irritable Bowel Syndrome: A Randomized, Placebo-controlled Trial.匹维溴铵 100mg 联合西甲硅油 300mg 治疗肠易激综合征腹痛腹胀的疗效:一项随机、安慰剂对照试验。
J Clin Gastroenterol. 2020 Apr;54(4):e30-e39. doi: 10.1097/MCG.0000000000001242.
2
Efficacy and safety of Modified Tongxie Yaofang in diarrhea-predominant irritable bowel syndrome management: A meta-analysis of randomized, positive medicine-controlled trials.痛泻要方加味治疗腹泻型肠易激综合征的疗效及安全性:随机、阳性药对照试验的荟萃分析
PLoS One. 2018 Feb 6;13(2):e0192319. doi: 10.1371/journal.pone.0192319. eCollection 2018.
3
Role of antispasmodics in the treatment of irritable bowel syndrome.
抗痉挛药在肠易激综合征治疗中的作用
World J Gastroenterol. 2014 May 28;20(20):6031-43. doi: 10.3748/wjg.v20.i20.6031.